[Schizophrenic disorders: current etiologic and clinical knowledge].

Schizophrénies: actualités etiopathogéniques et cliniques.

Publisher: Académie nationale de médecine Country of Publication: Netherlands NLM ID: 7503383 Publication Model: Print Cited Medium: Print ISSN: 0001-4079 (Print) Linking ISSN: 00014079 NLM ISO Abbreviation: Bull Acad Natl Med Subsets: MEDLINE

Publication: Paris : Académie nationale de médecine
Original Publication: Paris, Masson.

Brain/*pathology ; Schizophrenia/*etiology; Humans ; Schizophrenia/diagnosis ; Schizophrenic Psychology ; Schizotypal Personality Disorder/diagnosis

Brain anomalies associated with schizophrenic disorders may be of a cognitive, neurophysiological or neurological nature [the latter being relatively minor and nonspecific]. Brain imaging has revealed early anomalies such as cortical-subcortical atrophy and abnormal gyration. These anomalies can also be present in relatives free of schizophrenic symptoms. This raises the question of what determines the transition from vulnerability to clinical onset. There is now evidence that schizophrenic disorders are true brain diseases. This is based on neuropathological studies, brain imaging and clinical findings such as "soft" neurological signs (pyramidal and extrapyramidal symptoms, coordination difficulties, etc.). Cognitive dysfunctions such as attention and memory disorders and abnormal verbal fluency have also been described. Oculomotor pursuit and auditive evoked potentials have identified specific neurophysiological disorders such as N300 and P50 wave modifications. Schizophrenic disorders can also be associated with neuronal abnormalities, notably affecting factors involved in synaptic transmission and plasticity. For example, BDNF protein deficit is linked to certain late-onset forms of schizophrenia. Genetic studies are no longer focusing on a possible disease genotype but rather on phenotypic characteristics determined by simpler genotypes (P50 wave modulation, COMT and BDNF genes). The ultimate objective is to identify high-risk subjects, in order to shorten the treatment delay and thereby improve long-term outcome. The benefit of primary prophylaxis remains to be determined, however.

54

Date Created: 20060126 Date Completed: 20060223 Latest Revision: 20061115

20240513

16433464